NASDAQ: SLS
Sellas Life Sciences Group Inc Stock Forecast, Predictions & Price Target

Analyst price target for SLS

Based on 1 analyst offering 12 month price targets for Sellas Life Sciences Group Inc

Min Forecast
$7.00+266.49%
Avg Forecast
$7.00+266.49%
Max Forecast
$7.00+266.49%

Should I buy or sell SLS stock?

Based on 1 analyst offering ratings for Sellas Life Sciences Group Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SLS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SLS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their SLS stock forecasts and price targets.

SLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-16Find Out Why

1 of 1

Forecast return on equity

Is SLS forecast to generate an efficient return?

Company
46.79%
Industry
252.89%
Market
145.2%
SLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLS forecast to generate an efficient return on assets?

Company
37.88%
Industry
107.15%
SLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLS earnings per share forecast

What is SLS's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.27
Avg 2 year Forecast
-$0.34
Avg 3 year Forecast
-$0.33

SLS revenue forecast

What is SLS's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$21.9M
Avg 3 year Forecast
$56.1M

SLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLS$1.91$7.00+266.49%Strong Buy
CRBP$16.44$45.80+178.59%Buy
MDWD$18.55$31.00+67.12%Buy
TARA$5.14$21.00+308.56%Strong Buy
TLSA$1.84N/AN/A

Sellas Life Sciences Group Stock Forecast FAQ

Is Sellas Life Sciences Group Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SLS) stock is to Strong Buy SLS stock.

Out of 1 analyst, 1 (100%) are recommending SLS as a Strong Buy, 0 (0%) are recommending SLS as a Buy, 0 (0%) are recommending SLS as a Hold, 0 (0%) are recommending SLS as a Sell, and 0 (0%) are recommending SLS as a Strong Sell.

If you're new to stock investing, here's how to buy Sellas Life Sciences Group stock.

What is SLS's earnings growth forecast for 2025-2027?

(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 25.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.35%.

Sellas Life Sciences Group's earnings in 2025 is -$26,259,000.On average, 4 Wall Street analysts forecast SLS's earnings for 2025 to be -$28,293,430, with the lowest SLS earnings forecast at -$29,104,220, and the highest SLS earnings forecast at -$27,640,586. On average, 4 Wall Street analysts forecast SLS's earnings for 2026 to be -$36,317,097, with the lowest SLS earnings forecast at -$39,518,140, and the highest SLS earnings forecast at -$33,168,703.

In 2027, SLS is forecast to generate -$34,569,159 in earnings, with the lowest earnings forecast at -$36,117,032 and the highest earnings forecast at -$33,168,703.

What is SLS's revenue growth forecast for 2025-2027?

(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.

Sellas Life Sciences Group's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast SLS's revenue for 2025 to be $0, with the lowest SLS revenue forecast at $0, and the highest SLS revenue forecast at $0. On average, 3 Wall Street analysts forecast SLS's revenue for 2026 to be $2,305,698,679, with the lowest SLS revenue forecast at $2,237,150,026, and the highest SLS revenue forecast at $2,396,991,584.

In 2027, SLS is forecast to generate $5,905,187,359 in revenue, with the lowest revenue forecast at $4,565,698,256 and the highest revenue forecast at $7,386,196,260.

What is SLS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SLS) forecast ROA is 37.88%, which is lower than the forecast US Biotechnology industry average of 107.15%.

What is SLS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SLS price target, the average SLS price target is $7.00, with the highest SLS stock price forecast at $7.00 and the lowest SLS stock price forecast at $7.00.

The Wall Street analyst predicted that Sellas Life Sciences Group's share price could reach $7.00 by Jul 16, 2026. The average Sellas Life Sciences Group stock price prediction forecasts a potential upside of 266.49% from the current SLS share price of $1.91.

What is SLS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SLS) Sellas Life Sciences Group's current Earnings Per Share (EPS) is -$0.32. On average, analysts forecast that SLS's EPS will be -$0.27 for 2025, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at -$0.26. On average, analysts forecast that SLS's EPS will be -$0.34 for 2026, with the lowest EPS forecast at -$0.38, and the highest EPS forecast at -$0.32. In 2027, SLS's EPS is forecast to hit -$0.33 (min: -$0.34, max: -$0.32).

What is SLS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SLS) forecast ROE is 46.79%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.